Noema Pharma Secures CHF 130 Million in Series B Financing

Noema Pharma Secures CHF 130 Million in Series B Financing

Noema Pharma, a clinical-stage biotech company focused on the treatment of central nervous system (CNS) disorders, recently announced the successful close of a Series B extension financing round. With a significant investment from EQT Life Sciences, the total capital raised in this latest round reached CHF 130 million (approximately USD 147 million). This financing showcases the confidence that investors have in Noema's mission, steering towards innovative treatments for CNS disorders.

Details on the Financing and Investor Syndicate

The participation of EQT Life Sciences in Noema Pharma's financing aligns them with a strong syndicate, which includes other prominent investors such as Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises. Each of these partners contributes a wealth of experience and resources as Noema advances its groundbreaking therapies.

Significance of the Funding for Clinical Trials

The capital raised in this funding round will significantly bolster Noema Pharma’s four ongoing Phase 2 trials, with important data analysis expected in 2025. Specifically, these trials encompass several critical therapeutic areas, including:

Basimglurant (NOE-101)

Aiming to address severe pain caused by trigeminal neuralgia (TN) and seizures associated with tuberous sclerosis complex (TSC), this mGluR5 negative allosteric modulator is undergoing intensive Phase 2 trials.

Gemlapodect (NOE-105)

This PDE10a inhibitor is currently tested in a Phase 2b trial focusing on Tourette syndrome and is also being evaluated for childhood-onset fluency disorder, commonly known as stuttering.

NOE-115

This broad-spectrum monoamine modulator is in a Phase 2 trial targeting vasomotor symptoms as well as other menopause-related symptoms.

Expert Insights on Noema's Progress

Ilise Lombardo, MD, the CEO of Noema Pharma, remarked on the financing, expressing gratitude for the unwavering support from investors. She emphasized that their trust in Noema's vision is paramount for progressing the company’s clinical programs and ultimately making a significant impact on the lives of patients battling neurological conditions.

Felice Verduyn-van Weegen, a partner at EQT and newly appointed board member at Noema, also provided insights into the investment. She noted that Noema's innovative approach aligns perfectly with EQT’s investment philosophy, demonstrating a commitment to supporting late-stage clinical pipelines and emerging transformative therapies.

A Look Back: Previous Funding Rounds

This Series B extension follows a previous Series B financing round of CHF 103 million (USD 112 million) announced earlier and aligns with a CHF 54 million (approx. USD 60 million) Series A round that took place recently. This trajectory of funding showcases Noema Pharma's growing footprint in the biotech landscape since it was founded in 2019 with initial seed investment from Sofinnova Partners.

Understanding Noema Pharma

Noema Pharma is dedicated to pioneering a variety of first-in-disease therapeutics, directly targeting significant unmet medical needs associated with CNS disorders. The company is actively investing in clinical trials for conditions including seizures in Tuberous Sclerosis Complex, pain management in Trigeminal Neuralgia, Tourette syndrome, and menopause-related symptoms. With an eye towards 2025 for key data readouts, Noema continues to push boundaries in neuroscience.

Noema was established with backing from leading venture capital firms, including Sofinnova Partners, and continues to be supported by other prominent investors. This collaborative effort is essential for their ambitious agenda to transform patient care in the neuroscience sector.

Frequently Asked Questions

What is the total amount raised in the latest financing round?

Noema Pharma successfully raised CHF 130 million (approximately USD 147 million) in its recent Series B extension financing round.

Who are the key investors in this financing round?

The key investors include EQT Life Sciences alongside previous investors like Forbion, Jeito Capital, and others.

What will the new funding support?

The new financing will support Noema's four active Phase 2 trials along with developmental activities related to their pharmaceutical pipeline.

What conditions are being targeted in Noema's clinical trials?

Noema's clinical trials are targeting severe pain due to trigeminal neuralgia, seizures from tuberous sclerosis complex, Tourette syndrome, and vasomotor symptoms associated with menopause.

When are the key data readouts expected?

Key data readouts from these clinical trials are anticipated in 2025.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.